Pediatricians are urged to follow 2024 guidelines amid ACIP upheaval, vaccine hesitancy, and access issues as children head back to school.

Vaccination coverage among kindergartners in the United States declined during the 2024–2025 school year, while exemption rates rose, according to new findings from the CDC. Data from states and the ...

An expert discusses practical strategies for assessing atopic dermatitis severity, highlighting simple yet effective tools such as the Investigator Global Assessment (IGA) scale, palm-based body ...

An expert discusses the formal diagnostic criteria and diverse clinical presentations of atopic dermatitis, emphasizing patient-centered assessment, challenges in distinguishing it from similar ...

An expert discusses advancements in the management of atopic dermatitis, emphasizing early recognition, updated nonsteroidal treatments, accurate differential diagnosis, and the importance of ...

A look back at the FDA submissions and regulatory decisions in the pediatric health care space from July 2025.

An expert discusses the benefits and risks of topical corticosteroids (TCS) and calcineurin inhibitors in atopic dermatitis (AD) treatment, highlighting patient concerns about long-term adverse ...

Take a quick look at everything you may have missed last month, including the top FDA approvals and latest clinical updates. July 2025 brought new insights and policy shifts with direct implications ...

An expert discusses the importance of careful topical steroid use to minimize adverse effects in atopic dermatitis, while highlighting newer, more potent nonsteroidal treatments such as PDE4 and JAK ...

The FDA approved concizumab-mtci (Alhemo; Novo Nordisk) for hemophilia A/B without inhibitors, offering once-daily subcutaneous prophylaxis that significantly reduces bleeding rates.

An expert discusses how the stage and diverse presentations of atopic dermatitis, especially in underserved and darker-skinned patients, influence treatment decisions, highlighting the promise of new ...